Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Buy
79
DVAX Quote, Financials, Valuation and Earnings
Last price:
$15.63
Seasonality move
:
-4.48%
Day range:
$15.60 - $15.67
52-week range:
$9.20 - $15.73
Dividend yield:
0%
P/E ratio:
54.00x
P/S ratio:
6.53x
P/B ratio:
3.44x
Volume:
1.8M
Avg. volume:
4.2M
1-year change:
26.15%
Market cap:
$1.8B
Revenue:
$277.2M
EPS (TTM):
-$0.38
Analysts' Opinion
-
Consensus RatingDynavax Technologies Corp. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 1 Hold rating, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $20.50, Dynavax Technologies Corp. has an estimated upside of 40.76% from its current price of $15.63.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $15.63.
Fair Value
-
According to the consensus of 3 analysts, Dynavax Technologies Corp. has 40.76% upside to fair value with a price target of $20.50 per share.
DVAX vs. S&P 500
-
Over the past 5 trading days, Dynavax Technologies Corp. has overperformed the S&P 500 by 1.81% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Dynavax Technologies Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dynavax Technologies Corp. has grown year-over-year revenues for 7 quarters straight. In the most recent quarter Dynavax Technologies Corp. reported revenues of $94.9M.
Earnings Growth
-
Dynavax Technologies Corp. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Dynavax Technologies Corp. reported earnings per share of $0.21.
Enterprise value:
1.5B
EV / Invested capital:
--
Price / LTM sales:
6.53x
EV / EBIT:
141.48x
EV / Revenue:
4.47x
PEG ratio (5yr expected):
--
EV / Free cash flow:
18.34x
Price / Operating cash flow:
26.82x
Enterprise value / EBITDA:
79.06x
Gross Profit (TTM):
$274.9M
Return On Assets:
-4.47%
Net Income Margin (TTM):
-13.13%
Return On Equity:
-7.65%
Return On Invested Capital:
-5.15%
Operating Margin:
22.42%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $361.2M | $260.8M | $330.5M | $80.6M | $94.9M | |
| Gross Profit | $242.2M | $216.1M | $274.9M | $67.5M | $80.5M | |
| Operating Income | $36.7M | -$7.4M | $10.4M | $10.1M | $21.3M | |
| EBITDA | $43.5M | $496K | $18.7M | $12.1M | $23.4M | |
| Diluted EPS | $0.38 | $0.13 | -$0.38 | $0.11 | $0.21 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $852.7M | $932.9M | $835.7M | $926.2M | $814.3M | |
| Total Assets | $919.7M | $999.3M | $972.9M | $1.1B | $946.5M | |
| Current Liabilities | $528.9M | $244.1M | $54.3M | $70M | $106.8M | |
| Total Liabilities | $852.1M | $498.8M | $368M | $380.6M | $412.4M | |
| Total Equity | $67.6M | $500.6M | $604.9M | $681.4M | $534.1M | |
| Total Debt | $255.2M | $254.4M | $253.1M | $250.2M | $285M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $121.7M | $27.3M | $90.6M | $19.5M | $33.8M | |
| Cash From Investing | -$166.7M | -$61.6M | $152.4M | -$15.5M | $27.3M | |
| Cash From Financing | -$237K | -$1.4M | -$202.7M | $2.5M | -$61K | |
| Free Cash Flow | $117.8M | $22.7M | $80.5M | $18.1M | $32.6M | |
DVAX
Sector
Market Cap
$1.8B
$26.2M
Price % of 52-Week High
99.36%
51.54%
Dividend Yield
0%
0%
Shareholder Yield
11.99%
-1.64%
1-Year Price Total Return
26.15%
-16.92%
Beta (5-Year)
0.891
0.489
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$15.56
200-day SMA
Buy
Level
$10.90
Bollinger Bands (100)
Buy
Level
9.29 - 13.05
Chaikin Money Flow
Sell
Level
-1.5M
20-day SMA
Buy
Level
$14.35
Relative Strength Index (RSI14)
Buy
Level
86.11
ADX Line
Buy
Level
56.25
Williams %R
Neutral
Level
-27.7778
50-day SMA
Buy
Level
$12.33
MACD (12, 26)
Buy
Level
1.11
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
319.3M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.3904)
Buy
CA Score
(Annual)
Level (0.1513)
Buy
Beneish M-Score
(Annual)
Level (-2.973)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.9664)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Stock Forecast FAQ
In the current month, DVAX has received 1 Buy ratings 1 Hold ratings, and 1 Sell ratings. The DVAX average analyst price target in the past 3 months is $20.50.
-
Where Will Dynavax Technologies Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dynavax Technologies Corp. share price will rise to $20.50 per share over the next 12 months.
-
What Do Analysts Say About Dynavax Technologies Corp.?
Analysts are divided on their view about Dynavax Technologies Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dynavax Technologies Corp. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Dynavax Technologies Corp.'s Price Target?
The price target for Dynavax Technologies Corp. over the next 1-year time period is forecast to be $20.50 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 1 rates the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is DVAX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dynavax Technologies Corp. is a Hold. 1 of 3 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of DVAX?
You can purchase shares of Dynavax Technologies Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dynavax Technologies Corp. shares.
-
What Is The Dynavax Technologies Corp. Share Price Today?
Dynavax Technologies Corp. was last trading at $15.63 per share. This represents the most recent stock quote for Dynavax Technologies Corp.. Yesterday, Dynavax Technologies Corp. closed at $15.63 per share.
-
How To Buy Dynavax Technologies Corp. Stock Online?
In order to purchase Dynavax Technologies Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get DVAX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DVAX
Sector
P/E ratio
54.00x
23.89x
PEG ratio
--
-0.01x
P/B ratio
3.44x
1.81x
Price / LTM sales
6.53x
1.59x
Growth Metrics
DVAX
Sector
Revenue growth
17.67%
4.35%
Earnings growth
81.6%
9.8%
Revenue (5-year growth)
51.08%
6.41%
Earnings forecast
$0.08
-$0.18
Profitability
DVAX
Sector
Profitability FY 2024
$227.8M
$3.2M
Return on invested capital
-5.15%
-32.76%
Return on assets
-4.47%
-29.32%
Return on equity
-7.65%
-38.6%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
19
Estimated Next Earnings Date
Feb
4
Balance Sheet
DVAX
Sector
Total cash
$647.8M
$25.4M
Short term investments
$618M
$25.1M
Total assets
$986.3M
$74.7M
Long term debt
$285M
$3.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
75
AGX alert for Jan 17
Argan, Inc. [AGX] is up 16.4% over the past day.
Buy
80
ASTS alert for Jan 17
AST Spacemobile, Inc. [ASTS] is up 14.32% over the past day.
Buy
84
IREN alert for Jan 17
IREN Ltd. [IREN] is up 11.35% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
